maximum < may < mbd

Facettes : Author.f AffPays.f AffOrg.f AffRegion.f AffVille.f

List of bibliographic references

Number of relevant bibliographic references: 158.
[0-20] [0 - 20][0 - 50][20-40]

Ident.	Authors (with country if any)	Title
000000 (2009)	Susan P. Bruce [États-Unis]	Recent Developments in the Treatment of Rheumatoid Arthritis
000008 (2010)	P. Roll [Allemagne] ; A. Rubbert-Roth [Allemagne] ; H.-P. Tony [Allemagne]	Tocilizumab
000014 (2012)	Seiji Ohtori [Japon] ; Masayuki Miyagi [Japon] ; Yawara Eguchi [Japon] ; Gen Inoue [Japon] ; Sumihisa Orita [Japon] ; Nobuyasu Ochiai [Japon] ; Shunji Kishida [Japon] ; Kazuki Kuniyoshi [Japon] ; Junichi Nakamura [Japon] ; Yasuchika Aoki [Japon] ; Tetsuhiro Ishikawa [Japon] ; Gen Arai [Japon] ; Hiroto Kamoda [Japon] ; Miyako Suzuki [Japon] ; Masashi Takaso [Japon] ; Takeo Furuya [Japon] ; Gou Kubota [Japon] ; Yoshihiro Sakuma [Japon] ; Yasuhiro Oikawa [Japon] ; Tomoaki Toyone [Japon] ; Kazuhisa Takahashi [Japon]	Efficacy of epidural administration of anti-interleukin-6 receptor antibody onto spinal nerve for treatment of sciatica
000017 (2011)	Katsuaki Kanbe [Japon] ; Qian Chen [États-Unis] ; Atsushi Nakamura [Japon] ; Kaori Hobo [Japon]	Inhibition of MAP kinase in synovium by treatment with tocilizumab in rheumatoid arthritis
000020 (2011)	Taras Gout [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]	Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review
000031 (2005)	Shumpei Yokota [Japon] ; Takako Miyamae [Japon] ; Tomoyuki Imagawa [Japon] ; Shigeki Katakura [Japon] ; Rumiko Kurosawa [Japon] ; Masaaki Mori [Japon]	Clinical study of tocilizumab in children with systemic-onset juvenile idiopathic arthritis
000039 (2011)	Toshio Tanaka [Japon] ; Keisuke Hagihara [Japon] ; Yoshihito Shima [Japon] ; Masashi Narazaki [Japon] ; Atsushi Ogata [Japon] ; Atsushi Kumanogoh [Japon]	Tocilizumab, a humanized anti‐interleukin‐6 receptor antibody, for the treatment of autoimmune disorders
000043 (2009)	Kazuko Matsumoto [Japon] ; Takao Nagashima [Japon] ; Shino Takatori [Japon] ; Yuta Kawahara [Japon] ; Masaki Yagi [Japon] ; Masahiro Iwamoto [Japon] ; Hitoaki Okazaki [Japon] ; Seiji Minota [Japon]	Glucocorticoid and cyclosporine refractory adult onset Still’s disease successfully treated with tocilizumab
000056 (2015)	Yuliya Hellwig [Allemagne] ; Young E. Yoo [Allemagne] ; Marie L. Re [Allemagne] ; Oliver Andres [Allemagne] ; Matthias Braun [Allemagne] ; Paul G. Schlegel [Allemagne] ; Matthias Wölfl [Allemagne]	Fulminant skin GvHD with a cytokine pattern resemblant of cytokine release syndrome successfully treated with multimodal immunosuppression including tocilizumab
000068 (2012)	Yee Chiu [Royaume-Uni] ; Andrew J. K. Ostor [Royaume-Uni] ; Anthony Hammond [Royaume-Uni] ; Katharina Sokoll [Royaume-Uni] ; Marina Anderson [Royaume-Uni] ; Maya Buch [Royaume-Uni] ; Michael R. Ehrenstein [Royaume-Uni] ; Patrick Gordon [Royaume-Uni] ; Sophia Steer [Royaume-Uni] ; Ian N. Bruce [Royaume-Uni]	Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales
000074 (2010)	Keiichi Sumida [Japon] ; Yoshifumi Ubara [Japon] ; Junichi Hoshino [Japon] ; Tatsuya Suwabe [Japon] ; Rikako Hiramatsu [Japon] ; Eiko Hasegawa [Japon] ; Noriko Hayami [Japon] ; Masayuki Yamanouchi [Japon] ; Naoki Sawa [Japon] ; Fumi Takemoto [Japon] ; Kenmei Takaichi [Japon]	Etanercept-refractory adult-onset Still’s disease with thrombotic thrombocytopenic purpura successfully treated with tocilizumab
000083 (2012)	Yasuhiko Hirabayashi [Japon] ; Tomonori Ishii [Japon]	The DAS28-ESR cutoff value necessary to achieve remission under the new Boolean-based remission criteria in patients receiving tocilizumab
000091 (2012)	Sooha Kim [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]	Interleukin-6 and cytochrome-P450, reason for concern?
000096 (2009)	Hiroe Sato [Japon] ; Takehito Sakai [Japon] ; Toshiaki Sugaya [Japon] ; Yasuhiro Otaki [Japon] ; Kana Aoki [Japon] ; Katsushi Ishii [Japon] ; Hidehiro Horizono [Japon] ; Hiroshi Otani [Japon] ; Asami Abe [Japon] ; Noboru Yamada [Japon] ; Hajime Ishikawa [Japon] ; Kiyoshi Nakazono [Japon] ; Akira Murasawa [Japon] ; Fumitake Gejyo [Japon]	Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis
000120 (2011)	Rene Thonhofer [Autriche] ; Manuela Hiller [Autriche] ; Horst Just [Autriche] ; Markus Trummer [Autriche] ; Cornelia Siegel [Autriche] ; Christian Dejaco [Autriche]	Treatment of refractory adult-onset still’s disease with tocilizumab: report of two cases and review of the literature
000133 (2009)	Shin-Ya Kawashiri [Japon] ; Atsushi Kawakami [Japon] ; Satoshi Yamasaki [Japon] ; Takahiro Imazato [Japon] ; Naoki Iwamoto [Japon] ; Keita Fujikawa [Japon] ; Toshiyuki Aramaki [Japon] ; Mami Tamai [Japon] ; Hideki Nakamura [Japon] ; Hiroaki Ida [Japon] ; Tomoki Origuchi [Japon] ; Yukitaka Ueki [Japon] ; Katsumi Eguchi [Japon]	Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis
000149 (2010)	J. Wollenhaupt [Allemagne] ; K. Krüger [Allemagne]	Nicht-TNF-Biologika in der Therapiestrategie bei rheumatoider Arthritis
000150 (2012)	O. Psenak [Autriche] ; A. Studnicka-Benke [Autriche] ; R. Greil [Autriche]	Sicherheit der Immunsuppressiva
000169 (2015)	Yanli Zhuang [États-Unis] ; Dick E. De Vries [Pays-Bas] ; Zhenhua Xu [États-Unis] ; Stanley J. Marciniak Jr. [États-Unis] ; Dion Chen [États-Unis] ; Francisco Leon [États-Unis] ; Hugh M. Davis [États-Unis] ; Honghui Zhou [États-Unis]	Evaluation of disease‐mediated therapeutic protein–drug interactions between an anti–interleukin‐6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach
000172 (2011)	Maneesh Gogia [États-Unis] ; Daniel E. Furst [États-Unis]	Rheumatoid arthritis and pregnancy: Disease activity, pregnancy outcomes, and treatment options during pregnancy and lactation
000179 (2009)	Masahiko Mihara [Japon] ; Yoshiyuki Ohsugi [Japon] ; Tadamitsu Kishimoto	Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti‐interluekin‐6 receptor antibody

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "may" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "may" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    may
}}

---

This area was generated with Dilib version V0.6.34. Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021